Literature DB >> 21882222

Decreased bone mineral density and reduced bone quality in H(+) /K(+) ATPase beta-subunit deficient mice.

Reidar Fossmark1, Astrid K Stunes, Christiane Petzold, Helge L Waldum, Marina Rubert, Aina-Mari Lian, Janne E Reseland, Unni Syversen.   

Abstract

Proton pump inhibitors (PPIs) are widely used against gastroesophageal reflux disease. Recent epidemiological studies suggest that PPI users have an increased risk of fractures, but a causal relationship has been questioned. We have therefore investigated the skeletal phenotype in H(+) /K(+) ATPase beta-subunit knockout (KO) female mice. Skeletal parameters were determined in 6- and 20-month-old KO mice and in wild-type controls (WT). Whole body bone mineral density (BMD) and bone mineral content (BMC) were measured by dual energy X-ray absorptiometry (DXA). Femurs were examined with µCT analyses and break force were examined by a three-point bending test. Plasma levels of gastrin, RANKL, OPG, osteocalcin, leptin, and PTH were analyzed. KO mice had lower whole body BMC at 6 months (0.53 vs. 0.59 g, P = 0.035) and at 20 months (0.49 vs. 0.74 g, P < 0.01) compared to WT as well as lower BMD at 6 months (0.068 vs. 0.072 g/cm(2) , P = 0.026) and 20 months (0.067 vs. 0.077 g/cm(2) , P < 0.01). Mechanical strength was lower in KO mice at the age of 20 months (6.7 vs. 17.9 N, P < 0.01). Cortical thickness at 20 months and trabecular bone volume% at 6 months were significantly reduced in KO mice. Plasma OPG/RANKL ratio and PTH was increased in KO mice compared to controls. H(+) /K(+) ATPase beta subunit KO mice had decreased BMC and BMD, reduced cortical thickness and inferior mechanical bone strength. Whereas the mechanism is uncertain, these findings suggest a causal relationship between long-term PPI use and an increased risk of fractures.
Copyright © 2011 Wiley Periodicals, Inc.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 21882222     DOI: 10.1002/jcb.23337

Source DB:  PubMed          Journal:  J Cell Biochem        ISSN: 0730-2312            Impact factor:   4.429


  10 in total

Review 1.  The role of the gastrointestinal tract in calcium homeostasis and bone remodeling.

Authors:  J Keller; T Schinke
Journal:  Osteoporos Int       Date:  2013-03-28       Impact factor: 4.507

2.  Proton Pump Inhibitors, Histamine-2 Receptor Antagonists, and Hip Fracture Risk among Patients on Hemodialysis.

Authors:  Chandan Vangala; Jingbo Niu; Colin R Lenihan; William E Mitch; Sankar D Navaneethan; Wolfgang C Winkelmayer
Journal:  Clin J Am Soc Nephrol       Date:  2018-09-27       Impact factor: 8.237

3.  Proton pump inhibitors and fracture risk. The HUNT study, Norway.

Authors:  M Hoff; E Skovlund; S Skurtveit; H E Meyer; A Langhammer; A J Søgaard; U Syversen; S Forsmo; B Abrahamsen; B Schei
Journal:  Osteoporos Int       Date:  2019-11-18       Impact factor: 4.507

4.  A Proton Pump Inhibitor's Effect on Bone Metabolism Mediated by Osteoclast Action in Old Age: A Prospective Randomized Study.

Authors:  Yunju Jo; Eunkyoung Park; Sang Bong Ahn; Young Kwan Jo; Byungkwan Son; Seong Hwan Kim; Young Sook Park; Hyo Jeong Kim
Journal:  Gut Liver       Date:  2015-09-23       Impact factor: 4.519

5.  A Proton Pump Inhibitor in the Reformulation Setting: Bioequivalence and Potential Implications for Long-Term Safety.

Authors:  E Dubcenco; P M Beers-Block; L P Kim; P Schotland; J G Levine; C A McCloskey; E D Bashaw
Journal:  Clin Transl Sci       Date:  2017-06-15       Impact factor: 4.689

Review 6.  Adverse Effects of Proton Pump Inhibitors-Evidence and Plausibility.

Authors:  Reidar Fossmark; Tom C Martinsen; Helge L Waldum
Journal:  Int J Mol Sci       Date:  2019-10-21       Impact factor: 5.923

7.  Lansoprazole-induced osteoporosis via the IP3R- and SOCE-mediated calcium signaling pathways.

Authors:  Ziping Cheng; Yangjie Liu; Mengyuan Ma; Shiyu Sun; Zengqing Ma; Yu Wang; Liyuan Yu; Xuping Qian; Luning Sun; Xuehui Zhang; Yun Liu; Yongqing Wang
Journal:  Mol Med       Date:  2022-02-19       Impact factor: 6.354

8.  Do patients with gastroesophageal reflux disease exhibit compromised bone quality prior to proton pump inhibitor therapy?

Authors:  Kristin M Aasarød; Mats P Mosti; Malin T Finstad; Astrid K Stunes; Reidar Fossmark; Unni Syversen
Journal:  Bone Rep       Date:  2021-05-20

9.  Lansoprazole Upregulates Polyubiquitination of the TNF Receptor-Associated Factor 6 and Facilitates Runx2-mediated Osteoblastogenesis.

Authors:  Kenichi Mishima; Hiroshi Kitoh; Bisei Ohkawara; Tatsuya Okuno; Mikako Ito; Akio Masuda; Naoki Ishiguro; Kinji Ohno
Journal:  EBioMedicine       Date:  2015-11-17       Impact factor: 8.143

10.  Hypochlorhydria-induced calcium malabsorption does not affect fracture healing but increases post-traumatic bone loss in the intact skeleton.

Authors:  Melanie Haffner-Luntzer; Aline Heilmann; Verena Heidler; Astrid Liedert; Thorsten Schinke; Michael Amling; Timur Alexander Yorgan; Annika Vom Scheidt; Anita Ignatius
Journal:  J Orthop Res       Date:  2016-03-14       Impact factor: 3.494

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.